SCHEMBL6487238

SCHEMBL6487238

CCCCCOc1ccc(Cn2c(C)nc3c(C)cc(-c4nc(C)c(C(=O)OCC)o4)cc32)c(Cl)c1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.35
THRB P10828 3/20 0.35
PLA2G2A P14555 2/20 0.34
PIK3C2B O00750 2/20 0.33
DCTPP1 Q9H773 2/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
PPARA Q07869 1/20 0.33
TARBP2 Q15633 2/20 0.33
THRA P10827 1/20 0.32
PDCD4 Q53EL6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497985 0.93 PPARG (0.36) PPARGTHRBPLA2G2APIK3C2BDCTPP1
SCHEMBL6488200 0.89 PPARG (0.43) PPARGTHRBPLA2G2AALDH1A1LMNA
SCHEMBL6489123 0.87 LMNA (0.42) PPARGPIK3C2BALDH1A1LMNAGABRA2
SCHEMBL6489265 0.84 TARBP2 (0.42) PPARGPIK3C2BALDH1A1LMNAGABRA2
SCHEMBL6489388 0.84 GABRA1 (0.36) PPARGTHRBPLA2G2ADCTPP1LMNA
SCHEMBL6489090 0.84 PPARG (0.43) PPARGTHRBDCTPP1LMNAGABRA1
SCHEMBL6490173 0.82 RARB (0.47) PPARGDCTPP1
SCHEMBL6490563 0.81 PPARG (0.45) PPARGPLA2G2AALDH1A1PPARA
SCHEMBL6489425 0.81 PPARG (0.36) PPARGTHRBPLA2G2APIK3C2BDCTPP1
SCHEMBL6497730 0.80 PPARG (0.44) PPARGPLA2G2ADCTPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD PPARG 233/4885THRB 2919/4885PLA2G2A 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.